Filing Flows › Azenta (AZTA) › Q3 FY26 › vs Q2 FY26
Azenta (AZTA) Q3 FY26 vs Q2 FY26 (quarter over quarter)
Azenta's revenue rose $16.4M (+11%) from $145M in Q2 FY26 to $161M in Q3 FY26. The biggest changes: Multiomics +$9.2M (+14%); Sample Management Solutions +$7.2M (+9%).
Azenta, Q3 FY26: revenue $161M (+12% year over year), operating margin -2.6%, net earnings $2.5M, operating cash flow $1.4M. The chart draws each line against Q2 FY26, the increases inside each band.
Every line
| Line | Q3 FY26 | Q2 FY26 | Change | % |
|---|---|---|---|---|
| Core Products | $47.7M | $44.3M | $3.4M | +8% |
| Sample Repository Services | $40.6M | $36.8M | $3.8M | +10% |
| Sample Management Solutions | $88.3M | $81.1M | $7.2M | +9% |
| Multiomics | $72.9M | $63.7M | $9.2M | +14% |
| Revenue | $161M | $145M | $16.4M | +11% |
| Other income, net | $9.0M | $4.7M | $4.3M | +93% |
| Costs & expenses | $170M | $311M | −$140M | -45% |
| Operating costs | $165M | $311M | −$145M | -47% |
| Income tax | $2.4M | −$323K | $2.7M | — |
| Net earnings | $2.5M | −$161M | $163M | — |
| Cost of revenue | $88.8M | $82.8M | $6.1M | +7% |
| Research & development | $8.9M | $9.4M | −$580K | -6% |
| SG&A | $67.2M | $67.9M | −$719K | -1% |
| Other operating costs | $513K | $151M | −$150M | -100% |
| Operating cash sources | $20.8M | −$140M | $161M | — |
| Depreciation & amortization | $13.6M | $14.0M | −$422K | -3% |
| Share-based compensation | $4.8M | $6.4M | −$1.6M | -24% |
| Working capital & other | $19.4M | −$154M | $173M | — |
| Operating cash flow | $1.4M | $13.5M | −$12.1M | -89% |
| Capital expenditures | $6.6M | $7.4M | −$764K | -10% |
| Negative free cash flow (OCF − capex) | $5.2M | −$6.1M | $11.3M | — |
Questions
How much did Azenta's revenue grow quarter over quarter in Q3 FY26?
Azenta's revenue rose $16.4M (+11%) from $145M in Q2 FY26 to $161M in Q3 FY26.
What drove Azenta's revenue change in Q3 FY26?
Multiomics +$9.2M (+14%); Sample Management Solutions +$7.2M (+9%).